On 25 April 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) stunned Pfizer by issuing a negative opinion of Xeljanz (tofacitinib), an oral small molecule inhibitor of Janus kinase (JAK), in the treatment of moderate to severe rheumatoid arthritis (RA).
Highlights in this whitepaper include:
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: